Recombinat FGF21-Fc fusion Protein(Ampsource Biopharma)

An anoxic/oxic membrane bioreactor (AO) and three pilot-scale anaerobic side stream reactors (ASSR) coupled MBRs (ASSR-MBRs), packed with 0%, 25% and 50% carriers in ASSRs, were continuously operated to study the mechanisms for sludge reduction. Four systems showed efficient COD and NH₄⁺-N removal, while packing carriers significantly enhanced nitrogen removal. 25% filling fraction (AP₂₅) achieved the highest sludge reduction efficiency of 50.5% compared to 0% (21.7%) and 50% (39.7%). Compared to ASSR-MBR, carriers enhanced the release of dissolved organic matters, and accelerated the secretion of enzyme for cell lysis and hydrolysis. In AP₂₅, the presence of carriers prompted the formation of environment propitious to sludge reduction in bulk sludge. AP₂₅ tended to enrich hydrolytic, fermentative and denitrifying bacteria to accelerate hydrolysis process, while excessive carriers had negative effect on biomass stability and movement of carriers.

AP25 is an anti-tumor peptide with a high affinity for integrins. It exerts its anti-tumor activity by inhibiting angiogenesis and by directly inhibiting the growth of tumor cells. Its half-life time in vivo is only about 50 minutes, which limits its clinical application. In order to prolong the half-life time of AP25 while preserving its anti-tumor activity, several fusion proteins of AP25 and IgG4 Fc were designed and expressed; their anti-tumor activity and pharmacokinetics properties were evaluated. Firstly, four AP25-Fc fusion protein sequences were designed, and the corresponding proteins were expressed and purified. Based on the results of HUVEC migration inhibition assay, HUVEC and tumor cell proliferation inhibition assay and yields of expression by HEK293 cells, the fusion protein designated PSG4R was selected for further evaluation. The anti-tumor effect of PSG4R was then evaluated in vivo on HCT-116 nude mice xenograft model. And the pharmacokinetics properties of PSG4R were investigated in rats. The results showed that PSG4R could inhibit the growth of xenografts of human colon cancer cell line HCT-116 in nude mice by intravenous administration of 40 mg/kg once every two days. The half-life time of PSG4R was 56.270 ± 15.398 h. This study showed that the construction of AP25-Fc fusion protein could significantly prolong the half-life of AP25 while retaining its anti-tumor activity, which provides a new direction for new drug development of AP25.